Targeting RAS and PI3K in lung cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS not only drives the RAF/MAPK/ERK pathway but also directly activates PI3K to promote the PI3K/AKT/mTOR signaling [107].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [107]
In the citing paper
“Combing ARS-1620 with PI3K/AKT/mTOR pathway inhibitors could overcome resistance to ARS-1620 in both in vitro and in vivo models, including patient-derived xenograft models [110].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [110]
In the citing paper
“Analysis of a panel of KRAS G12C NSCLC cell lines treated with ARS-1620 revealed that variations of cellular response to KRAS G12C inhibition are associated with the suppression of MEK/ERK and PI3K/AKT signaling [110].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [110]
Citations
Cites
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Self-citationPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Self-citationTargeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Lim, K.-H., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.014 · Cited by 159
Cited by
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
“pathways activated by EGFR have also received great attention as potential targets for the development of new therapeutic drugs for lung cancer [165,166].”
BackgroundTargeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
“HCC 3 (5) — — — — — — — — 1 (33) 2 (67)”
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells
Shi, Q., Qin, L., Wei, W., Geng, F., Fan, R., Shik Shin, Y., Guo, D., Hood, L., Mischel, P. S., & Heath, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110865109 · Cited by 318
“This preferential activation of MAPK signaling pathways in response to EGF activation in GBM cells containing PTEN was validated by immunoblot analysis (Fig.”
BackgroundInfluentialSystemic treatment of soft-tissue sarcoma—gold standard and novel therapies
Linch, M., Miah, A. B., Thway, K., Judson, I. R., & Benson, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.26 · Cited by 216
Roccaro, A. M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Sahin, I., Kuhne, M., Cardarelli, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-564583 · Cited by 207
Chapter 1 Ras Signaling and Therapies
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02001-6 · Cited by 205
von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A. D., Taraborrelli, L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.014 · Cited by 196
“Many effector pathways downstream of KRAS have been implicated in KRAS-driven tumor development and maintenance (Castellano et al., 2013; Downward, 2008; Engelman et al., 2008; Gupta et al., 2007; Ling et al., 2012).”
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Madala, S. K., Schmidt, S., Davidson, C. R., Ikegami, M., Wert, S. E., & Hardie, W. D. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0237oc · Cited by 177
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
Müller, F., Lim, J. K. M., Bebber, C. M., Seidel, E., Tishina, S., Dahlhaus, A., Stroh, J., Beck, J., Yapici, F. I., Nakayama, K., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01096-8 · Cited by 160
“Point mutations within KRAS favor its active, GTP-bound state [2, 3].”
BackgroundCollins, M. A., Yan, W., Sebolt–Leopold, J. S., & Pasca di Magliano, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.052 · Cited by 133
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer
Moncho-Amor, V., de Cáceres, I. I., Bandrés, E., Martínez-Poveda, B., Orgaz, J. L., Sánchez‐Pérez, I., Zazo, S., Rovira, A., Albanell, J., Jiménez, B., et al. (2010) · Oncogene · doi:10.1038/onc.2010.449 · Cited by 125
Zhang, Y., Wang, L., Zhang, M., Jin, M., Bai, C., & Wang, X. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22722 · Cited by 114
“Phosphoinositide-3-kinas (PI3K) pathway is widely distributed in airway epithelia cells and is closely related to both inflammation and lung cancer (Downward, 2008).”
BackgroundLung tumor NF-κB signaling promotes T cell–mediated immune surveillance
Hopewell, E. L., Zhao, W., Fulp, W. J., Bronk, C. C., Lopez, A. S., Massengill, M., Antonia, S., Celis, E., Haura, E. B., Enkemann, S. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67250 · Cited by 103
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
“Ras activation stimulates cell proliferation via the Raf-MEK-ERK and PI3 kinase-Akt pathways, which involves development of carcinoma (15-17).”
The contribution of interleukin-2 to effective wound healing
Doersch, K., DelloStritto, D. J., & Newell‐Rogers, M. K. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216675773 · Cited by 82
“In the Pi3K pathway, Ras activation activates Pi3K, which goes on to activate Akt, which activates mTOR.(30) There are a myriad of subtypes of many of the participants in both the MAPK and Pi3K pathways.”
BackgroundSong, M., Wu, H., Wu, S., Ge, T., Wang, G., Zhou, Y., Sheng, S., & Jiang, J. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.034 · Cited by 76
“A549 harbors K-Ras mutation while H3255 and H460 habor EGFR mutations [11,12].”
BackgroundPotential Targets for Pancreatic Cancer Immunotherapeutics
Dodson, L. F., Hawkins, W. G., & Goedegebuure, P. S. (2011) · Immunotherapy · doi:10.2217/imt.11.10 · Cited by 74
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
Cras, T. D. L., Korfhagen, T. R., Davidson, C. R., Schmidt, S., Fenchel, M. C., Ikegami, M., Whitsett, J. A., & Hardie, W. D. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090123 · Cited by 69
Liu, C., Cao, Y., Zuo, Y., Zhang, C., Ren, S., Zhang, X., Wang, C., Zeng, Y., Ling, J., Liu, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.002 · Cited by 60
Cheng, X., Liu, Q., Li, H., Chen, K., Liu, Y., Guo, T., Shang, K., Yan, C., Cheng, G., & Lee, R. J. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2063-5 · Cited by 64
Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
Yamaki, H., Nakajima, M., Shimotohno, K., & Tanaka, N. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.60 · Cited by 56
Li, J., Gao, Z., Zhao, D., Zhang, L., Qiao, X., Zhao, Y., Ding, H., Zhang, P., Lu, J., Liu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0484 · Cited by 51
Russo, A. D., Rizzo, S., Bronte, G., Silvestris, N., Colucci, G., Gebbia, N., Bazan, V., & Fulfaro, F. (2009) · Oncology · doi:10.1159/000258497 · Cited by 53
“in a very large series (99 patients) reported a high concordance between primary and related metastases in terms of KRASmutational status. Further studies evaluating the possible switch of a CRC from wild-type to mutant KRASin patients receiving anti-EGFR mAbs are warranted.Some authors proposed a possible role of KRA…”
IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin
Ma, X., & Bai, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1110 · Cited by 57
“The PI3K/AKT signaling pathway regulates several normal cellular processes including cell proliferation, survival, growth and motility processes that are critical for tumorigenesis (17-21).”
BackgroundSchlaeth, M., Berger, S., Derer, S., Klausz, K., Lohse, S., Dechant, M., Lazar, G. A., Schneider‐Merck, T., Peipp, M., & Valerius, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01505.x · Cited by 54
Hu, T., Shen, H., Huang, H., Yang, Z., Zhou, Y., & Zhao, G. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000885 · Cited by 44
Oncogenic MAP2K1 mutations in human epithelial tumors
Choi, Y. L., Soda, M., Ueno, T., Hamada, T., Haruta, H., Yamato, A., Fukumura, K., Ando, M., Kawazu, M., Yamashita, Y., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs099 · Cited by 42
CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis
Truesdell, P. F., Ahn, J. C., Chander, H., Meens, J., Watt, K., Yang, X., & Craig, A. W. (2014) · Oncogene · doi:10.1038/onc.2014.280 · Cited by 40
Thompson, K. N., Whipple, R. A., Yoon, J. R., Lipsky, M., Charpentier, M. S., Boggs, A. E., Chakrabarti, K. R., Bhandary, L., Hessler, L. K., Martin, S. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6159 · Cited by 39
“Besides BCs, a significant body of evidence exists demonstrating the dual activation of the both the PI3K and Ras/MAPK pathway in a high proportion of human tumors, including lung [3, 34], ovarian [3], endometrial [35], prostate [36], colorectal [37, 38], bladder cancers [39], AML [35], and melanoma [35, 40], and it i…”
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 34
Chen, Y., Tan, K. A. L., Pang, L. Y., & Argyle, D. J. (2012) · BMC Veterinary Research · doi:10.1186/1746-6148-8-73 · Cited by 37
“In addition, the current data implicate the Ras/Raf/MEK/ERK pathway in resistance mechanisms to class I PI3K pathway inhibitors, supporting recent studies which generally recommend the use of combinatorial inhibitors targeting both PI3K/Akt signaling and Ras/ERK signaling [74,75].”
BackgroundInhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
“The second major pathway activated by Ras at the membrane is Ras/PI3K/AKT/mTOR (Downward, 2008; Sheridan and Downward, 2013).”
BackgroundBlocking the mTOR pathway: a drug discovery perspective
García-Echeverría, C. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390451 · Cited by 27
Singh, P., & Bast, F. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0774-2 · Cited by 26
Walker, D. M., Hayes, E. C., & Webb, L. J. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp51284c · Cited by 25
Kang, N., Cao, S., Jiang, B., Zhang, Q., Donkor, P. O., Zhu, Y., Qiu, F., & Gao, X. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104885 · Cited by 25
Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis
Yang, S., Xia, J., Yang, Z., Xu, M., & Li, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100311 · Cited by 24
Pan, Q., Liu, R., Banu, H., Ma, L., & Li, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.048 · Cited by 20
Pan, Q., Xu, J., & Ma, L. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12479 · Cited by 22
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
von Karstedt, S., & Walczak, H. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0249-4 · Cited by 22
Fentanyl stimulates tumor angiogenesis via activating multiple pro-angiogenic signaling pathways
Liu, W., Chen, Y., Xu, W. G., Wang, W., Tang, L., Xia, R., & Zhu, Q. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.038 · Cited by 19
Shimizu, M., Shibuya, H., & Tanaka, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-06916-y · Cited by 18
A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme
de Aquino, P. F., Carvalho, P. C., Nogueira, F. C. S., da Fonseca, C. O., Silva, J. C. T. D. S., Carvalho, M. D. G., Domont, G. B., Zanchin, N. I. T., & Fischer, J. D. S. D. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00183 · Cited by 17
Kuger, S., Flentje, M. P., & Djuzenova, C. S. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0514-5 · Cited by 18
“Especially the simultaneous inhibition of the MAPK and the PI3K/mTOR pathways, which are mutated in a multiplicity of human cancers, yielded promising results in various in vitro and in vivo studies [3, 14, 23, 46, 54, 64], since these signaling cascades are known to influence proliferation, cell growth, survival and…”
BackgroundXie, F., Li, P., Gong, J., Zhang, J., & Ma, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.089 · Cited by 16
Bao, X., Li, S., Gao, Y., Wang, J., & Zheng, N. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.03.035 · Cited by 16
Nath, R., Singha, S., Nath, D., Das, G., Patra, J. K., & Talukdar, A. D. (2022) · Applied Sciences · doi:10.3390/app122211749 · Cited by 17
Protein functional effector sncRNAs (pfeRNAs) in lung cancer
Brock, M. V., & Mei, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.013 · Cited by 15
Glucocorticoid receptor and RAS: an unexpected couple in cancer
Cirstea, I. C., Moll, H. P., & Tuckermann, J. P. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.11.002 · Cited by 16
PI3Ks—Drug Targets in Inflammation and Cancer
Wymann, M. P. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-3012-0_5 · Cited by 12
Linthicum, W., Thanh, M. H., Vitolo, M. I., & Wen, Q. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061613 · Cited by 11
Gable, T., Wang, Y., Clark, D. J., Kumari, P., Shetty, A. C., Li, M., & Mei, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.017 · Cited by 10
Zhu, Y., Hu, Q., & Li, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.074 · Cited by 12
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“KRAS not only drives the RAF/MAPK/ERK pathway but also directly activates PI3K to promote the PI3K/AKT/mTOR signaling [110].”
Li, G., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00024-9 · Cited by 7
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma
Desîlets, A., & Soulières, D. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000618 · Cited by 8
“Overexpression of upstream epidermal growth factor receptor (EGFR) and cross-interaction with RAS gain-of-function mutations are also expected to trigger PI3K pathway activation.(21,22) Approximately 15% to 20%of HNSCCs are associatedwith constitutive activation of thePI3KCA gene, making it themost commonly”
BackgroundAcquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 8
“[143,144] BRAF, a key kinase in the MAPK pathway, possesses activating mutations (e.g., V600E) that directly phosphorylate MEK without requiring KRAS activation.”
Genetic and epigenetic characteristics of patients with colorectal cancer from Uruguay
Vital, M., Carusso, F., Vergara, C., Neffa, F., Valle, A. D., & Esperón, P. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154264 · Cited by 5
AutoCancer as an automated multimodal framework for early cancer detection
Liu, L., Xiong, Y., Zheng, Z., Huang, L., Song, J., Lin, Q., Tang, B., & Wong, K. (2024) · iScience · doi:10.1016/j.isci.2024.110183 · Cited by 5
“47,48 The Ras signaling pathway also influences the EGFR pathway, which contributesto thepathogenesisof varioustumors,includingNSCLC.”
Immunotherapy of Pancreatic Cancer
Stevenson, R. L., Goodman, M. D., & Saif, M. W. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_12 · Cited by 5
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Xu, L., Zheng, S.-X., Mei, L., Yang, K., Wang, Y., Zhou, Q., Kong, X., Zheng, M.-Y., Jiang, H., & Xie, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01053-2 · Cited by 5
“143D selectively inhibits the constitutive activation of KRAS signaling pathways It has been reported that KRAS-RAF-MEK-ERK and KRAS-PI3K-AKT are the two major signaling pathways in KRAS-mutated tumor cells [21], and these pathways regulate cell proliferation, migration, and differentiation [22, 23].”
BackgroundRelationship between PI3K Mutation and Sodium-Iodide Symporter in Anaplastic Thyroid Carcinoma
Bozorg-Ghalati, F., & Hedayati, M. (2015) · Cited by 4
Guo, G., Yang, C., Li, G., Li, H., Ma, Q., Guo, Q., & Yang, X. (2015) · Chemical Papers · doi:10.1515/chempap-2015-0131 · Cited by 2
“PDK1 is a key protein in the mediation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway and PI3K/Akt/mTOR have a key role in the pathogenesis of various forms of human cancer, including lung cancer (Downward, 2008; Papadimitrakopoulou, 2012).”
BackgroundMolecular networks in respiratory epithelium carcinomas
Pallis, A. G., Karamouzis, M. V., Konstantinopoulos, P. A., & Papavassiliou, A. G. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.014 · Cited by 2
Sayed, A., Hossain, M. H., Islam, E., & Asgar, M. A. (2023) · Asian Journal of Biology · doi:10.9734/ajob/2023/v17i1312 · Cited by 1
Cemmi, F., Stella, G. M., Zorzetto, M., Inghilleri, S., Morbini, P., Dore, R., & Pozzi, E. (2010) · Università degli Studi di Pavia · doi:10.6092/2039-1404.123.666 · Cited by 1
Zhang, Y., & Gao, Q. (2024) · Case Reports in Oncology · doi:10.1159/000540355 · Cited by 1
“Genomic analyses have ushered in novel strategies for diagnosing sMPLC. PI3K/AKT/mTOR and RAS/RAF/MEK are two crucial signaling cascades that are activated by RAS to regulate tumorigenesis, progression, and metastasis in lung cancer [15].”
BackgroundFilho, J. C. M. R. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2009.tde-06102009-094118
Yoon, J., Koo, K.-H., & Choi, K. (2011)
Malek, S., & McCormick, F. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.02001-5
Targeting MAPK Pathways: Novel Therapeutic Approaches for Human Disease
Nirupam, P., & Jagdish, K. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00732
Hasan, M. S. A., Hossain, M. I., Hossan, R., Banu, H., Akter, K., Akbor, M. S., Mandal, P., Mizan, M., Bristy, A. H., & Sumaya, U. H. (2025) · Journal of Chemistry Insights and Discoveries · doi:10.71193/jcid.20250006
Fusion genes in high-grade serous ovarian cancer
Rausio, H. (2023) · UTUPub (University of Turku)
Janesha, U. G. S., Chiu, C.-T., Mh, T., Chang, K.-M., Chien, C., Huang, H., Li, H.-Y., Yang, Y.-C., Lu, H., Pan, C.-T., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06027-7
“NFκB is widely recognized for regulating a diverse set of genes that govern immunity, inflammation, cell proliferation, survival, and apoptosis [37 ], including interleukins, BCL2 [38 ], VEGFA [39 ], FASL [40 ], and TGM2 [39 ].”
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
Unlocking drug sensitivity in KRAS
MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279
Metadata
- Authors
- Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Corresponding author
- Downward, Julian
- ORCID
- Downward, Julian
- Venue
- Nature Medicine
- Published
- 2008-12
- Volume
- 14
- Issue
- 12
- Pages
- 1315-1316
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1999354555
- Cited by
- 80
- References
- 9
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 4 · 2013: 4 · 2012: 4
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Ras, phosphatidylinositol 3-kinase, lung cancer, PI3K inhibitors, MAPK kinase inhibitors, combination therapy, tumor growth inhibition
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Enzyme Inhibitors, Humans, Lung Neoplasms, ras Proteins, Phosphatidylinositol 3-Kinases, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.